Dendrimers as Nanocarriers for Nucleic Acid and Drug Delivery in Cancer Therapy

Dendrimers are highly branched polymers with easily modifiable surfaces. This makes them promising structures for functionalization and also for conjugation with drugs and DNA/RNA. Their architecture, which can be controlled by different synthesis processes, allows the control of characteristics such as shape, size, charge, and solubility. Dendrimers have the ability to increase the solubility and bioavailability of hydrophobic drugs. The drugs can be entrapped in the intramolecular cavity of the dendrimers or conjugated to their functional groups at their surface. Nucleic acids usually form complexes with the positively charged surface of most cationic dendrimers and this approach has been extensively employed. The presence of functional groups in the dendrimer’s exterior also permits the addition of other moieties that can actively target certain diseases and improve delivery, for instance, with folate and antibodies, now widely used as tumor targeting strategies. Dendrimers have been investigated extensively in the medical field, and cancer treatment is one of the greatest areas where they have been most used. This review will consider the main types of dendrimer currently being explored and how they can be utilized as drug and gene carriers and functionalized to improve the delivery of cancer therapy.

[1]  Yiyun Cheng,et al.  Surface-engineered dendrimers with a diaminododecane core achieve efficient gene transfection and low cytotoxicity. , 2014, Bioconjugate chemistry.

[2]  Jong-sang Park,et al.  Arginine modified PAMAM dendrimer for interferon beta gene delivery to malignant glioma. , 2013, International journal of pharmaceutics.

[3]  Tamer Refaat,et al.  Cancer active targeting by nanoparticles: a comprehensive review of literature , 2015, Journal of Cancer Research and Clinical Oncology.

[4]  J. Baker,et al.  Efficient transfer of genetic material into mammalian cells using Starburst polyamidoamine dendrimers. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[5]  Q. Zhong,et al.  Poly(amidoamine) Dendrimer-Doxorubicin Conjugates: In Vitro Characteristics and Pseudosolution Formulation in Pressurized Metered-Dose Inhalers. , 2016, Molecular pharmaceutics.

[6]  Ryan M. Pearson,et al.  Size and Surface Charge of Engineered Poly(amidoamine) Dendrimers Modulate Tumor Accumulation and Penetration: A Model Study Using Multicellular Tumor Spheroids. , 2016, Molecular pharmaceutics.

[7]  Patrick Couvreur,et al.  Stimuli-responsive nanocarriers for drug delivery. , 2013, Nature materials.

[8]  T. Niidome,et al.  Hydrophobic cavity formed by oligopeptide for doxorubicin delivery based on dendritic poly(L-lysine) , 2014, Journal of biomaterials science. Polymer edition.

[9]  Sanjeev Banerjee,et al.  PAMAM dendrimers as promising nanocarriers for RNAi therapeutics , 2015 .

[10]  T. Niidome,et al.  Folate-PEG-appended dendrimer conjugate with α-cyclodextrin as a novel cancer cell-selective siRNA delivery carrier. , 2012, Molecular pharmaceutics.

[11]  P. Oliveira,et al.  Doxorubicin‐Induced Cardiotoxicity: From Bioenergetic Failure and Cell Death to Cardiomyopathy , 2014, Medicinal research reviews.

[12]  Y. Pei,et al.  PEGylated PAMAM Dendrimer-Doxorubicin Conjugates: In Vitro Evaluation and In Vivo Tumor Accumulation , 2010, Pharmaceutical Research.

[13]  D. Owen,et al.  Characterisation and tumour targeting of PEGylated polylysine dendrimers bearing doxorubicin via a pH labile linker. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[14]  Donald A Tomalia,et al.  Dendrimers in biomedical applications--reflections on the field. , 2005, Advanced drug delivery reviews.

[15]  Min Zhang,et al.  Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells. , 2009, Small.

[16]  T. Higashi,et al.  Inhibitory effect of siRNA complexes with polyamidoamine dendrimer/α-cyclodextrin conjugate (generation 3, G3) on endogenous gene expression. , 2011, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[17]  Andrea Danani,et al.  Computational insights into the interactions between DNA and siRNA with "rigid" and "flexible" triazine dendrimers. , 2010, Biomacromolecules.

[18]  E. Schacht,et al.  Structure-activity relationships of poly(L-lysines): effects of pegylation and molecular shape on physicochemical and biological properties in gene delivery. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[19]  James R. Dewald,et al.  A New Class of Polymers: Starburst-Dendritic Macromolecules , 1985 .

[20]  V. Kabanov,et al.  Interaction of Astramol Poly(propyleneimine) Dendrimers with Linear Polyanions , 1999 .

[21]  R. Duncan,et al.  Dendrimer biocompatibility and toxicity. , 2005, Advanced drug delivery reviews.

[22]  T. B. Kirk,et al.  A polyamidoamne dendrimer functionalized graphene oxide for DOX and MMP-9 shRNA plasmid co-delivery. , 2017, Materials science & engineering. C, Materials for biological applications.

[23]  N. K. Jain,et al.  A review on comparative study of PPI and PAMAM dendrimers , 2016, Journal of Nanoparticle Research.

[24]  D. Tomalia,et al.  Poly(amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications. , 2001, Drug discovery today.

[25]  J. S. Choi,et al.  Poly(ethylene glycol)-block-poly(L-lysine) dendrimer: novel linear polymer/dendrimer block copolymer forming a spherical water-soluble polyionic complex with DNA. , 1999, Bioconjugate chemistry.

[26]  Dawei Chen,et al.  Redox and pH dual responsive poly(amidoamine) dendrimer-poly(ethylene glycol) conjugates for intracellular delivery of doxorubicin. , 2016, Acta biomaterialia.

[27]  Jong-sang Park,et al.  Comparison between arginine conjugated PAMAM dendrimers with structural diversity for gene delivery systems. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[28]  Sanjiv Lalwani,et al.  Mimicking PAMAM Dendrimers with Ampholytic, Hybrid Triazine Dendrimers: A Comparison of Dispersity and Stability. , 2009, Macromolecules.

[29]  Vipul Bansal,et al.  Trastuzumab-grafted PAMAM dendrimers for the selective delivery of anticancer drugs to HER2-positive breast cancer , 2016, Scientific Reports.

[30]  S. Jain,et al.  A PEGylated dendritic nanoparticulate carrier of fluorouracil. , 2003, International journal of pharmaceutics.

[31]  Takuro Niidome,et al.  In vitro gene transfection using dendritic poly(L-lysine). , 2002, Bioconjugate chemistry.

[32]  J. Fréchet,et al.  Designing dendrimers for drug delivery. , 1999, Pharmaceutical science & technology today.

[33]  M. Morilla,et al.  Uptake and intracellular traffic of siRNA dendriplexes in glioblastoma cells and macrophages , 2011, International journal of nanomedicine.

[34]  A. Giuliano,et al.  Current status of anti-human epidermal growth factor receptor 2 therapies: predicting and overcoming herceptin resistance. , 2013, Clinical breast cancer.

[35]  Eun-Kyung Lim,et al.  Novel hyaluronic acid (HA) coated drug carriers (HCDCs) for human breast cancer treatment , 2008, Biotechnology and bioengineering.

[36]  H. M. Nielsen,et al.  Comparison of Polymeric siRNA Nanocarriers in a Murine LPS-Activated Macrophage Cell Line: Gene Silencing, Toxicity and Off-Target Gene Expression , 2011, Pharmaceutical Research.

[37]  P. Swaan,et al.  Surface acetylation of polyamidoamine (PAMAM) dendrimers decreases cytotoxicity while maintaining membrane permeability. , 2007, Bioconjugate chemistry.

[38]  J. Leroux,et al.  Delivery of Nucleic Acids through the Controlled Disassembly of Multifunctional Nanocomplexes , 2009 .

[39]  C. Hawker,et al.  Preparation of polymers with controlled molecular architecture. A new convergent approach to dendritic macromolecules , 1990 .

[40]  J. Reineke,et al.  Conjugation to Poly(amidoamine) Dendrimers and Pulmonary Delivery Reduce Cardiac Accumulation and Enhance Antitumor Activity of Doxorubicin in Lung Metastasis. , 2016, Molecular pharmaceutics.

[41]  Keerti Jain,et al.  Dendrimer as nanocarrier for drug delivery , 2014 .

[42]  Daniel G. Anderson,et al.  Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose , 2016, Proceedings of the National Academy of Sciences.

[43]  J. Baker,et al.  The interaction of plasmid DNA with polyamidoamine dendrimers: mechanism of complex formation and analysis of alterations induced in nuclease sensitivity and transcriptional activity of the complexed DNA. , 1997, Biochimica et biophysica acta.

[44]  E. Bustos,et al.  Applications of dendrimers in drug delivery agents, diagnosis, therapy, and detection , 2014 .

[45]  C. Watala,et al.  PAMAM dendrimers: destined for success or doomed to fail? Plain and modified PAMAM dendrimers in the context of biomedical applications. , 2015, Journal of pharmaceutical sciences.

[46]  Youqing Shen,et al.  Targeted Co-delivery of PTX and TR3 siRNA by PTP Peptide Modified Dendrimer for the Treatment of Pancreatic Cancer. , 2017, Small.

[47]  Jong-sang Park,et al.  Arginine-conjugated polypropylenimine dendrimer as a non-toxic and efficient gene delivery carrier. , 2007, Biomaterials.

[48]  T. Hianik,et al.  siRNA carriers based on carbosilane dendrimers affect zeta potential and size of phospholipid vesicles. , 2012, Biochimica et biophysica acta.

[49]  C. M. Roth,et al.  PAMAM-RGD conjugates enhance siRNA delivery through a multicellular spheroid model of malignant glioma. , 2009, Bioconjugate chemistry.

[50]  D. Lu,et al.  The strategy to improve gene transfection efficiency and biocompatibility of hyperbranched PAMAM with the cooperation of PEGylated hyperbranched PAMAM. , 2014, International journal of pharmaceutics.

[51]  P. Kesharwani,et al.  Dendrimer toxicity: Let's meet the challenge. , 2010, International journal of pharmaceutics.

[52]  M. Ramezani,et al.  Synthesis of efficient gene delivery systems by grafting pegylated alkylcarboxylate chains to PAMAM dendrimers: Evaluation of transfection efficiency and cytotoxicity in cancerous and mesenchymal stem cells , 2015, Journal of biomaterials applications.

[53]  Viney Lather,et al.  Dendrimers in drug delivery and targeting: Drug-dendrimer interactions and toxicity issues , 2014, Journal of pharmacy & bioallied sciences.

[54]  J. Fréchet,et al.  Convergent dendrons and dendrimers: from synthesis to applications. , 2001, Chemical reviews.

[55]  T. Minko,et al.  Surface-engineered targeted PPI dendrimer for efficient intracellular and intratumoral siRNA delivery. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[56]  Sonam Choudhary,et al.  Impact of Dendrimers on Solubility of Hydrophobic Drug Molecules , 2017, Front. Pharmacol..

[57]  Seungpyo Hong,et al.  Prolonged blood circulation and enhanced tumor accumulation of folate-targeted dendrimer-polymer hybrid nanoparticles. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[58]  Jianqing Gao,et al.  Overcoming drug resistance of MCF-7/ADR cells by altering intracellular distribution of doxorubicin via MVP knockdown with a novel siRNA polyamidoamine-hyaluronic acid complex. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[59]  N. Chaniotakis,et al.  Dendrimers as tunable vectors of drug delivery systems and biomedical and ocular applications , 2015, International journal of nanomedicine.

[60]  N. Weiner,et al.  Application of membrane-based dendrimer/DNA complexes for solid phase transfection in vitro and in vivo. , 2000, Biomaterials.

[61]  Ijeoma F. Uchegbu,et al.  The Lower-Generation Polypropylenimine Dendrimers Are Effective Gene-Transfer Agents , 2002, Pharmaceutical Research.

[62]  A. Chauhan Dendrimers for Drug Delivery , 2018, Molecules.

[63]  Y. Omidi,et al.  Toxicogenomics of drug delivery systems: Exploiting delivery system-induced changes in target gene expression to enhance siRNA activity , 2007, Journal of drug targeting.

[64]  Vijay Mishra,et al.  The development, characterization and in vivo anti-ovarian cancer activity of poly(propylene imine) (PPI)-antibody conjugates containing encapsulated paclitaxel. , 2015, Nanomedicine : nanotechnology, biology, and medicine.

[65]  P. Ortega,et al.  Carbosilane dendrimers NN8 and NN16 form a stable complex with siGAG1. , 2011, Colloids and surfaces. B, Biointerfaces.

[66]  Neil B. McKeown,et al.  Engineering of Dendrimer Surfaces to Enhance Transepithelial Transport and Reduce Cytotoxicity , 2003, Pharmaceutical Research.

[67]  Jiangyu Wu,et al.  Dendrimers as Carriers for siRNA Delivery and Gene Silencing: A Review , 2013, TheScientificWorldJournal.

[68]  N. Turro,et al.  Using Ethidium Bromide To Probe the Interactions between DNA and Dendrimers , 2000 .

[69]  Seungpyo Hong,et al.  Tweaking dendrimers and dendritic nanoparticles for controlled nano-bio interactions: potential nanocarriers for improved cancer targeting , 2015, Journal of drug targeting.

[70]  D. Tomalia,et al.  CommentaryDendrimers in biomedical applications—reflections on the field☆☆☆ , 2012 .

[71]  Clive J Roberts,et al.  Preferential liver gene expression with polypropylenimine dendrimers. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[72]  E. Simanek,et al.  Polycationic triazine-based dendrimers: effect of peripheral groups on transfection efficiency. , 2009, New journal of chemistry = Nouveau journal de chimie.

[73]  Gediminas Mainelis,et al.  Inhibition of lung tumor growth by complex pulmonary delivery of drugs with oligonucleotides as suppressors of cellular resistance , 2010, Proceedings of the National Academy of Sciences.

[74]  G. Salzano,et al.  Multifunctional Polymeric Micelles Co-loaded with Anti–Survivin siRNA and Paclitaxel Overcome Drug Resistance in an Animal Model of Ovarian Cancer , 2015, Molecular Cancer Therapeutics.

[75]  C. M. Roth,et al.  Binding and transport of PAMAM‐RGD in a tumor spheroid model: The effect of RGD targeting ligand density , 2011, Biotechnology and bioengineering.

[76]  Bo Hye Kim,et al.  Biodegradable PAMAM ester for enhanced transfection efficiency with low cytotoxicity. , 2009, Biomaterials.

[77]  E. Buhleier,et al.  "Cascade"- and "Nonskid-Chain-like" Syntheses of Molecular Cavity Topologies , 1978 .

[78]  N. K. Jain,et al.  Generation Dependent Safety and Efficacy of Folic Acid Conjugated Dendrimer Based Anticancer Drug Formulations , 2014, Pharmaceutical Research.

[79]  V. Torchilin,et al.  Design, synthesis, and characterization of pH-sensitive PEG-PE conjugates for stimuli-sensitive pharmaceutical nanocarriers: the effect of substitutes at the hydrazone linkage on the ph stability of PEG-PE conjugates. , 2007, Bioconjugate chemistry.

[80]  Min Zhang,et al.  Multifunctional Triblock Nanocarrier (PAMAM-PEG-PLL) for the Efficient Intracellular siRNA Delivery and Gene Silencing , 2011, ACS nano.

[81]  K. Ewert,et al.  Structural polymorphism of DNA-dendrimer complexes. , 2003, Physical review letters.

[82]  Francis C Szoka,et al.  Designing dendrimers for biological applications , 2005, Nature Biotechnology.

[83]  S. Álvarez,et al.  In vivo delivery of siRNA to the brain by carbosilane dendrimer. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[84]  Jong-sang Park,et al.  Enhanced transfection efficiency of PAMAM dendrimer by surface modification with L-arginine. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[85]  Jiahai Zhang,et al.  Comparison of generation 3 polyamidoamine dendrimer and generation 4 polypropylenimine dendrimer on drug loading, complex structure, release behavior, and cytotoxicity , 2011, International journal of nanomedicine.

[86]  K. Leong,et al.  In vitro gene delivery using polyamidoamine dendrimers with a trimesyl core. , 2005, Biomacromolecules.

[87]  Prashant Kesharwani,et al.  Recent advances in dendrimer-based nanovectors for tumor-targeted drug and gene delivery. , 2015, Drug discovery today.

[88]  Y. Liu,et al.  In vitro evaluation of dendrimer-polymer hybrid nanoparticles on their controlled cellular targeting kinetics. , 2013, Molecular pharmaceutics.

[89]  H. Jono,et al.  Potential use of lactosylated dendrimer (G3)/α-cyclodextrin conjugates as hepatocyte-specific siRNA carriers for the treatment of familial amyloidotic polyneuropathy. , 2012, Molecular pharmaceutics.

[90]  F. Szoka,et al.  Polyamidoamine cascade polymers mediate efficient transfection of cells in culture. , 1993, Bioconjugate chemistry.

[91]  Ben J Boyd,et al.  A comparison of changes to doxorubicin pharmacokinetics, antitumor activity, and toxicity mediated by PEGylated dendrimer and PEGylated liposome drug delivery systems. , 2012, Nanomedicine : nanotechnology, biology, and medicine.

[92]  Eichman,et al.  The use of PAMAM dendrimers in the efficient transfer of genetic material into cells. , 2000, Pharmaceutical science & technology today.

[93]  Valérie Maraval,et al.  "Lego" chemistry for the straightforward synthesis of dendrimers. , 2003, The Journal of organic chemistry.

[94]  Yuan Ping,et al.  Structure‐Invertible Nanoparticles for Triggered Co‐Delivery of Nucleic Acids and Hydrophobic Drugs for Combination Cancer Therapy , 2015 .

[95]  E. W. Meijer,et al.  About Dendrimers: Structure, Physical Properties, and Applications. , 1999, Chemical reviews.

[96]  C. Hawker,et al.  Hyperbranched Macromolecules via a Novel Double‐Stage Convergent Growth Approach , 1991 .

[97]  Takeshi Mori,et al.  Structural advantage of dendritic poly(L-lysine) for gene delivery into cells. , 2007, Bioorganic & medicinal chemistry.

[98]  R. Juliano,et al.  Tat-Conjugated PAMAM Dendrimers as Delivery Agents for Antisense and siRNA Oligonucleotides , 2005, Pharmaceutical Research.

[99]  G. Takemura,et al.  Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. , 2007, Progress in cardiovascular diseases.

[100]  M. Zloh,et al.  Cationic poly-L-lysine dendrimer complexes doxorubicin and delays tumor growth in vitro and in vivo. , 2013, ACS nano.

[101]  B. Jiang,et al.  Tumor penetrability and anti-angiogenesis using iRGD-mediated delivery of doxorubicin-polymer conjugates. , 2014, Biomaterials.

[102]  C. Kanthou,et al.  Systemic antiangiogenic activity of cationic poly-L-lysine dendrimer delays tumor growth , 2010, Proceedings of the National Academy of Sciences.

[103]  E. Simanek,et al.  Triazine dendrimers as nonviral gene delivery systems: effects of molecular structure on biological activity. , 2009, Bioconjugate chemistry.

[104]  Huixin He,et al.  Labile catalytic packaging of DNA/siRNA: control of gold nanoparticles "out" of DNA/siRNA complexes. , 2010, ACS nano.

[105]  H. Tajmir-Riahi,et al.  Structural analysis of doxorubicin-polymer conjugates. , 2015, Colloids and surfaces. B, Biointerfaces.

[106]  Michael Rubinstein,et al.  A Self-Consistent Mean Field Model of a Starburst Dendrimer: Dense Core vs Dense Shell , 1996 .

[107]  J. Leroux,et al.  siRNA nanocarriers based on methacrylic acid copolymers. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[108]  Donald A. Tomalia,et al.  Dendrimers with Hydrophobic Cores and the Formation of Supramolecular Dendrimer−Surfactant Assemblies , 1997 .

[109]  M. Morilla,et al.  Increased brain radioactivity by intranasal 32P-labeled siRNA dendriplexes within in situ-forming mucoadhesive gels , 2012, International journal of nanomedicine.

[110]  F. Szoka,et al.  Chloride Accumulation and Swelling in Endosomes Enhances DNA Transfer by Polyamine-DNA Polyplexes* , 2003, Journal of Biological Chemistry.

[111]  Jun Wang,et al.  Smart Superstructures with Ultrahigh pH-Sensitivity for Targeting Acidic Tumor Microenvironment: Instantaneous Size Switching and Improved Tumor Penetration. , 2016, ACS nano.

[112]  Charles L. Wilkins,et al.  Double Exponential Dendrimer Growth , 1995 .

[113]  E. W. Meijer,et al.  Dendrimers: relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 125I-labelled polyamidoamine dendrimers in vivo. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[114]  X. Shuai,et al.  Co-delivery of doxorubicin and siRNA with reduction and pH dually sensitive nanocarrier for synergistic cancer therapy. , 2014, Small.

[115]  J. Ježek,et al.  Synthesis of Dendrimers: Convergent and Divergent Approaches , 2012 .

[116]  T. Minko,et al.  Internally cationic polyamidoamine PAMAM-OH dendrimers for siRNA delivery: effect of the degree of quaternization and cancer targeting. , 2009, Biomacromolecules.

[117]  F. Szoka,et al.  The influence of polymer structure on the interactions of cationic polymers with DNA and morphology of the resulting complexes , 1997, Gene Therapy.

[118]  S. Tucker,et al.  Spectroscopic investigations of poly(propyleneimine)dendrimers using the solvatochromic probe phenol blue and comparisons to poly(amidoamine) dendrimers. , 2001, Analytical chemistry.

[119]  M. Markowicz,et al.  Evaluation of poly(amidoamine) dendrimers as potential carriers of iminodiacetic derivatives using solubility studies and 2D-NOESY NMR spectroscopy , 2012, Journal of biological physics.

[120]  N. K. Jain,et al.  Generation dependent cancer targeting potential of poly(propyleneimine) dendrimer. , 2014, Biomaterials.

[121]  M. Grinstaff,et al.  Therapeutic and diagnostic applications of dendrimers for cancer treatment. , 2008, Advanced drug delivery reviews.

[122]  Vladimir P Torchilin,et al.  Mixed Nanosized Polymeric Micelles as Promoter of Doxorubicin and miRNA-34a Co-Delivery Triggered by Dual Stimuli in Tumor Tissue. , 2016, Small.

[123]  B. Nanjwade,et al.  Dendrimers: emerging polymers for drug-delivery systems. , 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[124]  T. Niidome,et al.  Efficient delivery of siRNA using dendritic poly(L-lysine) for loss-of-function analysis. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[125]  Daniel G. Anderson,et al.  Ionizable amphiphilic dendrimer-based nanomaterials with alkyl-chain-substituted amines for tunable siRNA delivery to the liver endothelium in vivo. , 2014, Angewandte Chemie.

[126]  V. Torchilin,et al.  Lipid modified triblock PAMAM-based nanocarriers for siRNA drug co-delivery. , 2013, Biomaterials.

[127]  S. Betigeri,et al.  Surface-modified and internally cationic polyamidoamine dendrimers for efficient siRNA delivery. , 2008, Bioconjugate chemistry.

[128]  Qiang Zhang,et al.  Surface-engineered dendrimers in gene delivery. , 2015, Chemical reviews.

[129]  K. Valerie,et al.  Click synthesis of a polyamidoamine dendrimer-based camptothecin prodrug. , 2015, RSC advances.

[130]  M. Morilla,et al.  Ethylendiamine core PAMAM dendrimers/siRNA complexes as in vitro silencing agents. , 2009, International journal of pharmaceutics.

[131]  V. Torchilin Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery , 2014, Nature Reviews Drug Discovery.

[132]  C. Dufès,et al.  Transferrin-bearing polypropylenimine dendrimer for targeted gene delivery to the brain. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[133]  J. Ong,et al.  Design of a paclitaxel prodrug conjugate for active targeting of an enzyme upregulated in breast cancer cells. , 2014, Molecular pharmaceutics.

[134]  Keerti Jain,et al.  Dendrimers in anticancer drug delivery: mechanism of interaction of drug and dendrimers , 2016, Artificial cells, nanomedicine, and biotechnology.

[135]  K. Yoshikawa,et al.  Time-dependent complex formation of dendritic poly(L-lysine) with plasmid DNA and correlation with in vitro transfection efficiencies. , 2003, Organic & biomolecular chemistry.

[136]  Vladimir P. Torchilin,et al.  Dendrimers for siRNA Delivery , 2013, Pharmaceuticals.

[137]  D. Tomalia Birth of a new macromolecular architecture: dendrimers as quantized building blocks for nanoscale synthetic polymer chemistry , 2005 .

[138]  N. McKeown,et al.  The influence of surface modification on the cytotoxicity of PAMAM dendrimers. , 2003, International journal of pharmaceutics.

[139]  T. Niidome,et al.  In vivo siRNA delivery with dendritic poly(L-lysine) for the treatment of hypercholesterolemia. , 2009, Molecular bioSystems.

[140]  H. Tajmir-Riahi,et al.  Targeted conjugation of breast anticancer drug tamoxifen and its metabolites with synthetic polymers. , 2016, Colloids and surfaces. B, Biointerfaces.

[141]  Riyi Shi,et al.  Polyethylene glycol immediately repairs neuronal membranes and inhibits free radical production after acute spinal cord injury , 2002, Journal of neurochemistry.

[142]  T. Imae,et al.  Nanogel formation consisting of DNA and poly(amido amine) dendrimer studied by static light scattering and atomic force microscopy. , 2004, Biomacromolecules.

[143]  Huixin He,et al.  Multifunctional nanomedicine platform for cancer specific delivery of siRNA by superparamagnetic iron oxide nanoparticles-dendrimer complexes. , 2011, Current drug delivery.

[144]  Y. Omidi,et al.  Polypropylenimine dendrimer-induced gene expression changes: The effect of complexation with DNA, dendrimer generation and cell type , 2005, Journal of drug targeting.

[145]  Craig J Hawker,et al.  Efficiency and fidelity in a click-chemistry route to triazole dendrimers by the copper(i)-catalyzed ligation of azides and alkynes. , 2004, Angewandte Chemie.

[146]  Zheng-Rong Lu,et al.  Targeted intracellular codelivery of chemotherapeutics and nucleic acid with a well-defined dendrimer-based nanoglobular carrier. , 2009, Biomaterials.

[147]  Yuanjie Liu,et al.  Lipid-dendrimer hybrid nanosystem as a novel delivery system for paclitaxel to treat ovarian cancer. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[148]  T. Minko,et al.  Targeted Nanomedicine for Suppression of CD44 and Simultaneous Cell Death Induction in Ovarian Cancer: An Optimal Delivery of siRNA and Anticancer Drug , 2013, Clinical Cancer Research.

[149]  Kim Ngoc Phan,et al.  Pegylated dendrimer and its effect in fluorouracil loading and release for enhancing antitumor activity. , 2013, Journal of biomedical nanotechnology.

[150]  J. Baker,et al.  Regulation of in vitro gene expression using antisense oligonucleotides or antisense expression plasmids transfected using starburst PAMAM dendrimers. , 1996, Nucleic acids research.

[151]  R. Kannan,et al.  Hydroxyl PAMAM dendrimer-based gene vectors for transgene delivery to human retinal pigment epithelial cells. , 2015, Nanoscale.

[152]  F. Hirayama,et al.  Potential Use of Dendrimer/α-Cyclodextrin Conjugate as a Novel Carrier for Small Interfering RNA (siRNA) , 2006 .

[153]  Benjamin P. Roberts,et al.  Molecular Dynamics of Poly(L-lysine) Dendrimers with Naphthalene Disulfonate Caps , 2009 .

[154]  M. B. Banaszak Holl,et al.  Poly(amidoamine) Dendrimer–Methotrexate Conjugates: The Mechanism of Interaction with Folate Binding Protein , 2014, Molecular pharmaceutics.

[155]  H. M. Nielsen,et al.  Elucidating the molecular mechanism of PAMAM-siRNA dendriplex self-assembly: effect of dendrimer charge density. , 2011, International journal of pharmaceutics.

[156]  Dong Soo Yun,et al.  Dendrimer-Inspired Nanomaterials for the in Vivo Delivery of siRNA to Lung Vasculature. , 2014, Nano letters.

[157]  Ashutosh Tiwari,et al.  Polymeric Micellar Structures for Biosensor Technology , 2016 .